Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2020 · 10-Q
Revenue$10.52M$10.52M+110.3% vs Q3 2019 Net Income-$282.89K-$282.89KN/M vs Q3 2019 EPS Diluted-$0.02-$0.02N/M vs Q3 2019 Gross Profit$6,014,347+99.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived-$106,598N/M Free Cash Flowderived-$126,854N/M Margins · derivedGross margin57.2%−3.2 pt vs Q3 2019
Operating margin-1.7%+38.0 pt vs Q3 2019
Net margin-2.7%+28.7 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 9, 2020 · 40 d after period end